Social Media Ideas for Prescription Drugs And Biologics

New Biosimilar Legislation Addresses Inflation Reduction Act Delay Provision

Key Update The Biosimilars Access and Affordability Act has been reintroduced in both chambers, which would create clearer criteria for delaying Medicare price negotiation of a re...

Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability

(StatePoint) Biological drug products (biologics) — which can be made of sugars, proteins, living cells, tissues, or a combination of these — are providing new options for patients...

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

Biologics Standards for Innovation, Quality and Access

This GEN Spotlight on Biologics Standards for Innovation, Quality and Access brings together experts from across biopharma, standards development, and analytical science to examine...

Biosimilars Boast Big Savings But Face IP Risks, Report Says

There are no biosimilar drugs in development for 90% of biologic products set to lose their patent exclusivity by 2034, according to a report released Thursday by the Association f...

The Spinoff: How Biosimilars Are Becoming Wholesalers' Next Hit Show

By Bryce Platt, PharmD For more than a decade, the answer to “Where do drug wholesalers make their money?” has been generic drugs. Although wholesaler revenues are linked mo...

Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document

By Sara W. Koblitz —

GLOBE and MFN Pricing: Implications for Cross-Border Drug Development and Transactions

On Oct. 2, 2026, the Centers for Medicare & Medicaid Services (CMS) published the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) Model. GLOBE is a manda...

<![CDATA[FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV,...

This Week in 340B: September 15 – 21, 2026

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 3...

The 340B Squeeze: Academic Medical Centers and Large Health Systems Have the Most to Lose

Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest. Most of the 340B debate...

Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document

Nothing to See Here: FDA Issues Interchangeable Biosimilars Strategy Document Anonymous (not verified) Fri, 09/25/2026 - 00:58 pharmagather item url Nothin...

Preorder DCI’s New 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 12, 2026, Drug Channels Institute will release our 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The U.S. prescription drug marke...

<![CDATA[Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act]]>

<![CDATA[A Steadying Trajectory: Biopharma Review and Outlook]]>

ACI’s 6th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA

The American Conference Institute’s (ACI’s) virtual 6th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA is scheduled to take place from October 20-29, 20...

<![CDATA[How Can Restricting Compounded Peptides Affect Current Gray Market Users?]]>

Proposed H.R. 10336 Would Balance Innovation, Access to Dietary Supplements—Yet Change the Definition

On September 10, 2026, Congresswoman Diana Harshbarger (R-TN) introduced H.R. 10336—the Dietary Supplement Innovation Act—which would modernize the U.S. Food and Drug Administratio...

<![CDATA[What Would a Category One Designation Mean for Peptides?]]>

Dietary Supplement Innovation Act Aims to Address Drug Preclusion Concerns

Representative Diana Harshbarger (R-TN) recently introduced the Dietary Supplement Innovation Act (H.R. 10336), legislation that would amend the Federal Food, Drug, and Cosmetic Ac...

5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight

The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the...

<![CDATA[What Moments in FDA’s Review Process Should Patients and Providers be Watching Closely?]]>

Biosimilars in Brazil: Intellectual Property, Regulatory and Market Landscape

Biological drugs, or biologics, are now a well-established class of therapeutic products worldwide. Unlike conventional small-molecule drugs, which are generally obtained through c...

The IRA Fixed One Medicare Part D Distortion—But Patients Now Face New Tradeoffs (rerun)

This week, we're rerunning some popular posts while we put the finishing touches on DCI’s 2026-27 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Clic...